Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Anaeropharma Science

Request full access

Working on the development of novel therapeutics to target hypoxic environment in solid cancers

Tokyo, JapanFounded 2004Biotech & Life Sciences

About Anaeropharma Science

Established in 2004, Anaeropharma Science, Inc. is a biopharmaceutical venture that originated from the research of Tetsuya Tonoike, who would later become a director, at the Industrial Technology Center of Saga. The company was founded by Yoshihiro Kakeji, a professor at Kobe University's Graduate School of Medicine, who now serves as an advisor, alongside co-founder and current President & CEO Koichi Sugiue. The firm's core focus is on developing novel anti-cancer drugs by leveraging anaerobic bacteria of the genus *Bifidobacterium*. This unique therapeutic approach, termed In-situ Delivery and Production System (IDPS), utilizes recombinant *Bifidobacterium longum* as a vector to selectively deliver and produce therapeutic proteins directly within the hypoxic microenvironments of solid tumors. The technology addresses a significant challenge in oncology: effectively targeting the oxygen-deficient core of tumors, which is often resistant to conventional therapies like chemotherapy and radiation. The genetically modified bacteria are administered intravenously and are engineered to germinate and proliferate exclusively in these hypoxic zones, transforming the tumor itself into a factory for anti-cancer agents. This targeted mechanism is designed to minimize damage to healthy tissues, a common side effect of traditional cancer treatments. Anaeropharma Science's lead pipeline candidate, APS001F, is a recombinant *Bifidobacterium longum* that expresses a cytosine deaminase, an enzyme that converts a separately administered prodrug (5-FC) into the potent anti-cancer drug 5-FU directly at the tumor site. The company is also exploring other therapeutic proteins, such as immunomodulatory agents, to be delivered via its platform. The business model centers on research and development, with the goal of partnering with larger pharmaceutical companies for late-stage clinical trials, manufacturing, and commercialization. This strategy is supported by a series of strategic funding rounds and collaborations, including a significant joint development agreement with Chugai Pharmaceutical Co., Ltd. announced in 2024.

Source: Dealroom company data

At a glance

Status
Operational
Employees
4
Open positions
None listed
Dealroom signal
55.9/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
OtherOther financing Jan 2020 $0 — Undisclosed —
LATE VC✓Equity / VC Jul 2017 $13M $53M Seventure Partners · INCJ · Shinsei Corporate Investment · Mitsubishi UFJ Capital —
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Anaeropharma Science website traffic

Latest recorded traffic for Anaeropharma Science is 70 monthly website visits, down 41.7% over the last three months. Anaeropharma Science's team grew 0% over the past year.

Latest monthly visits70 3-month web change-41.7% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Anaeropharma Science in the Tokyo ecosystem

Live from Dealroom

The Anaeropharma Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Watervein Partners

Series A1 investor entered at this stage

  • INCJ

Series B and later4 investors entered at this stage

  • Seventure Partners
  • Shinsei Corporate Investment
  • Mitsubishi UFJ Capital
  • Syngenta

Other known investors1 additional known investor

  • Mitsui Global Investment
Team profiled 3 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇯🇵 Japan100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Anaeropharma Science on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Anaeropharma Science’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.